SingHealth IMU is led by two directors (Clinical & Scientific and Admin & Ops) and staffed by a team of dedicated fully qualified coordinators, specialist nurses and resident physicians, who have been trained in ICH-GCP.
The directors also sit on the Executive Committee, which is in charge of its academic and operational affairs. It is made up of representatives from SingHealth institutions.
The Executive Committee reports to an Advisory Board that charts the overall direction and sets the units governing policies. It consists of representatives from SingHealth Institutions, Duke-NUS Graduate Medical School Singapore and private entities.
Dr Matthew Ng, Director (Clinical & Scientific)
Dr Matthew Ng completed his PhD from the Institute of Cancer Research in London. He is a medical oncologist at the National Cancer Centre Singapore, and is currently the oncology lead for upper gastrointestinal (GI) cancers and Director of the Investigational Medicine Unit (IMU).
Research interests: Development of novel therapeutic strategies for patients particularly in GI cancers.
Dr Jenny Low, Deputy Director (Clinical & Scientific)
Dr Jenny Low have obtained her Master of Public Health from Johns Hopkins University, Bloomberg School of Public Health. She is a Board Certified senior consultant with the department of Infectious Diseases in Singapore General Hospital (SGH), and also the co-director of the Viral Research and Experimental Medicine Centre@ SingHealth Duke-NUS (ViREMiCS) in the SingHealth Duke NUS AMC. She led the early dengue infection and outcome (EDEN) study that detailed in several publications, clinical dengue in adults. She was the lead clinical investigator in the first proof-of-concept clinical trial on the use of Celgosivir as an anti-dengue drug (CELADEN) in Singapore. She was also the lead PI in an investigator led trial that tested the role of pre-existing cross-reactive antibodies in influencing vaccine efficacy using JE and YF vaccinations. She was awarded the National Clinician Scientist Award in 2016 to study the effects of long term inflammatory drug use on vaccination response and outcomes.
Research interests: Early phase clinical trials of viral therapeutics and vaccine development, role of innate immune response in modulating the outcome of infection or vaccination
Ms Sue Tee, Director (Administration & Operations)
Prior to working at SingHealth, Sue was with several pharmaceutical companies for 12 years playing a marketing and sales role in oncology for South East Asian countries. She has completed several successful commercialisation product projects in the biopharmaceutical field for companies to market in Singapore.
In addition to her role in Administration and Operations at SingHealth IMU conducting early phase trials, Sue also holds the Director, Clinical Trials Coordinating Centre role in SingHealth. Under her leadership, CTCC works closely with the SingHealth institutions' clinical trial units, investigators and research community to leverage existing clinical trials' strength to synergise efforts for maximised efficiency and quality in the field of clinical research / trials. Her extensive knowledge of clinical trials enables her to assist in collaborations among multi-sites.
